Semaglutide/BPC-157

Description

• Semaglutide/BPC-157 Research & Chemical Profile

  “Semaglutide / BPC-157” is an informal research pairing that combines a GLP-1 receptor agonist (semaglutide) with the pentadecapeptide BPC-157, which is being investigated for cytoprotective and pro-healing effects. This section summarizes identifiers, rationale for combined exploration, safety considerations, and key references for each constituent.

   

  Chemical Structure / Identifiers — Semaglutide

  Property	Detail
  Common Name	Semaglutide
  Class	GLP-1 receptor agonist (modified human GLP-1 analog)
  Sequence	H-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(N-[γ-Glu-(C18 fatty diacid)])-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Asp-Ser-Ala-Arg-Leu-Gln-Gly-Glu-Arg-Gly-OH
  Molecular Formula	C187H291N45O59
  Molecular Weight	≈ 4113.58 g/mol
  CAS Number	910463-68-2
  PubChem CID	56843307
  Synonyms	GLP-1 (7-37) analog; Ozempic (brand name); Wegovy (brand name)

   

  Chemical Structure / Identifiers — BPC-157

  Property	Detail
  Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 aa)
  Molecular Formula	C62H98N16O22
  Molecular Weight	≈ 1419.55 g/mol
  CAS Number	137525-51-0
  PubChem CID	9941957
  Synonyms	Body Protection Compound-157; PL 14736; bepecin (research name)

   

  Primary Research Focus (Constituents)

  • Semaglutide: Approved GLP-1 receptor agonist for glycemic control and weight management; slows gastric emptying and reduces appetite; ongoing research into cardiovascular and metabolic outcomes.
  • BPC-157: Preclinical evidence for gastrointestinal mucosal protection, tendon/ligament healing, angiogenesis support, and anti-inflammatory signaling.

   

  Combined Rationale (Research Context)

  • Complementary Mechanisms: Semaglutide addresses metabolic pathways, while BPC-157 is reported to support tissue repair and cytoprotection in animal models. The pairing has been hypothesized for research exploring metabolic recovery alongside tissue healing, but this remains speculative.
  • Evidence Base: No controlled human trials evaluating the combined use of semaglutide and BPC-157 exist; most literature evaluates each constituent separately.

   

  Safety / Limitations

  Regulatory Status – Semaglutide is FDA-approved for type 2 diabetes/obesity at specific doses; BPC-157 is not approved for human use by major regulators.

  Variability – Semaglutide from unlicensed sources may differ in identity/purity; BPC-157 is typically sold as a research chemical with no standardized manufacturing.

  Human Data – Limited or no human data on combined administration; dosing, pharmacokinetics, and long-term safety unknown.

  Anti- Doping – Semaglutide is not currently on major anti-doping banned lists, but BPC-157 is prohibited by some sports bodies; confirm current regulations before any laboratory use with athletes.

   

  Key Publications / References

  • PubChem Compound Summary: Semaglutide (CID 56843307) https://pubchem.ncbi.nlm.nih.gov/compound/56843307
  • Semaglutide clinical review: FDA prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209637s010lbl.pdf
  • PubChem Compound Summary: BPC-157 (CID 9941957) https://pubchem.ncbi.nlm.nih.gov/compound/9941957
  • Pentadecapeptide BPC-157 enhances tendon outgrowth and fibroblast migration. J Appl Physiol. 2010. PubMed: https://pubmed.ncbi.nlm.nih.gov/21030672/
  • Stable gastric pentadecapeptide BPC-157: review of anti-ulcer and systemic cytoprotective effects. World J Gastroenterol. 2015. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC4717094/

  Disclaimer: For research background only. Not medical advice. “Semaglutide / BPC-157” is an informal concept; combined use has not been validated in human trials.